

GU ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs		
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS					
SWOG	S1314-Blad, COXEN Neoadj. Chemo + Cyst	1	Y	1	GC+CYST	230	113	48	27	12	5	1	08/28/2014	223	118
				2	DDMVAC+CYST		111	47	28	14	6	2			
						224	95	55	26	11	3				
	S1500-pRCC,Adv, Sunitinib vs MET inhib	1	Y	1	Sunitinib	180	13	12	4	3	1	0	07/25/2016	196	87
				2	Cabozantinib		12	10	4	3	2	0			
				3	Crizotinib		13	11	5	3	2	1			
				4	Savolitinib		12	10	5	1	0	0			
						50	43	18	10	5	1				
	S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y	1	TICE BCG	969	10	10	9	5	2	0	02/24/2017	136	61
				2	Tokyo-172 BCG		11	11	11	8	4	2			
				3	Prime + Tokyo-172 BCG		11	11	10	8	2	2			
						32	32	30	21	8	4				
	S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab	1	Y	1	Atezolizumab	148	11	11	10	6	4	1	03/13/2017	133	58
							11	11	10	6	4	1			
Yes	A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	1	E		Total Registrations		2	2	0	0	0	0	11/23/2016	56	33
							2	2	0	0	0	0			
	NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel	1	E		Total Registrations		1	1	1	1	1	0	08/24/2017		6
							1	1	1	1	1	0			
				2	Total Registrations		1	1	1	1	1	1	08/24/2017		
							1	1	1	1	1	1			
No	EA8141-UTUC, HG, Chemo then Surg	1	E		Total Registrations		8	4	2	0	0	0	02/23/2016	153	75
							8	4	2	0	0	0			
	R0924-Pros, NADT+WPRT vs. NADT+P&SV RT	1	E		Total Registrations		52	25	12	6	1	1	11/25/2013		163
							52	25	12	6	1	1			